Drug Profile

VX 522

Alternative Names: mRNA-3692; VX-522; VXc-0522; VXc-522

Latest Information Update: 17 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Moderna Therapeutics; Vertex Pharmaceuticals
Developer Vertex Pharmaceuticals
Class Antifibrotics; RNA
Mechanism of Action Cystic fibrosis transmembrane conductance regulator expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Cystic fibrosis

Most Recent Events

03 Feb 2025 Phase-I/II clinical trials in Cystic fibrosis in USA, Australia, Belgium, Canada, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom (Inhalation) (NCT05668741)
06 Jan 2023 Phase-I clinical trials in Cystic fibrosis in USA (Inhalation) (NCT05668741)
31 Dec 2022 VX 522 receives Fast Track designation for Cystic fibrosis [Inhalation] in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com